Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance
- 1st Edition - August 1, 2026
- Latest edition
- Editors: Mariza Vorster, Mike Sathekge
- Language: English
Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance serves as a vital resource in the evolving field of nuclear medicine, highli… Read more
Theranostic Approaches in Nuclear Medicine as a Strategy to Overcome Cancer Treatment Resistance serves as a vital resource in the evolving field of nuclear medicine, highlighting the transformative potential of theranostic strategies that combine targeted diagnostic imaging with precision radionuclide therapies. The content explores the integration of theranostic techniques into treatment paradigms for cancer and other diseases, emphasizing the unique advantages of nuclear medicine therapies, including reduced side effects, improved quality of life, outpatient accessibility, and cost-effectiveness. For an academic audience, this volume equips clinicians and researchers with insights to enhance patient outcomes by effectively integrating these innovative therapies into clinical practice.
The book addresses the pressing challenge of treatment resistance in oncology, providing healthcare professionals with a comprehensive understanding of the latest advancements and their applications. By embracing these advancements, healthcare professionals can contribute to personalized medicine and better address treatment resistance in their patients.
The book addresses the pressing challenge of treatment resistance in oncology, providing healthcare professionals with a comprehensive understanding of the latest advancements and their applications. By embracing these advancements, healthcare professionals can contribute to personalized medicine and better address treatment resistance in their patients.
- Provides a thorough examination of theranostic approaches in nuclear medicine, detailing how these strategies integrate targeted diagnostic imaging with precision radionuclide therapies to combat treatment resistance
- Explores the most recent advancements in radionuclide therapies, focusing on their practical applications in clinical settings
- Highlights the unique advantages of nuclear medicine therapies, equipping healthcare professionals with the knowledge they need to enhance patient outcomes
Scientists and scholars in the fields of oncology, nuclear medicine, radiopharmaceuticals, and related disciplines
1. Introduction
2. Mechanisms of Treatment Resistance
3. Principles of Theranostics in Nuclear Medicine
4. Theranostic Agents, Development and Novel Delivery Approaches
5. Applications in Oncology
6. Emerging Applications Beyond Oncology
7. Combination Strategies, Tandem Approaches and Place in Treatment Landscape
8. Dosimetry and Personalized Treatment Planning
9. Challenges and Limitations in Theranostic Applications
10. Conclusions and Future Directions
2. Mechanisms of Treatment Resistance
3. Principles of Theranostics in Nuclear Medicine
4. Theranostic Agents, Development and Novel Delivery Approaches
5. Applications in Oncology
6. Emerging Applications Beyond Oncology
7. Combination Strategies, Tandem Approaches and Place in Treatment Landscape
8. Dosimetry and Personalized Treatment Planning
9. Challenges and Limitations in Theranostic Applications
10. Conclusions and Future Directions
- Edition: 1
- Latest edition
- Published: August 1, 2026
- Language: English
MV
Mariza Vorster
Prof Mariza Vorster is an associate Professor and Head of Department at the University of Kwa-Zulu Natal’s Department of Nuclear Medicine, which currently includes three hospital sites in Durban. She has significant experience in the use of alpha and beta targeted radionuclide therapies and started treatment with Ac-225-PSMA and DOTATATE in KZN in Jan of 2023. In 2023 she was awarded the Maurits W Geerlings award by the ICPO for her significant contributions with regards to Ac225 therapy. Prof Vorster is an IAEA expert and collaborator, who has authored and co-authored over 120 peer-reviewed publications (including several book chapters). Her research interests include the use of novel Ga-68 based tracer applications and theranostics aimed at solving important clinical problems. She is the President of the College of Nuclear Physicians and serves as an examiner, convenor and senator for the Colleges of Medicine of South Africa
Affiliations and expertise
University of Kwazulu-Natal, South AfricaMS
Mike Sathekge
Dr Mike Sathekge is at the forefront of specialist training and was elected President of the Colleges of Medicine of South Africa, the national specialist examining body for all medical disciplines. He is Professor and Head of the Nuclear Medicine Department at University of Pretoria. Previously, he was President of the International Society of Radiolabeled Blood Elements (ISORBE) and past Secretary General of the World Federation of Nuclear Medicine and Biology (WFNMB). Sathekge is Chairman of the Medical Research Council of South Africa. He has performed several first-in-human studies and introduced peptide receptor radionuclide therapy and peptide radioligand therapy in Africa, as well as 225AcPSMA for prostate cancer. He is a recipient of several key awards for research and service, including being rated as an internationally acclaimed researcher by the National Research Foundation. His publication and presentation record earned him editorial roles on peer-reviewed journals. He is CoEditor in Chief of the Seminars of Nuclear Medicine and member of the Academy of Science of South Africa (ASSAf)
Affiliations and expertise
University of Pretoria, South Africa